UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009709 |
|---|---|
| Receipt number | R000011382 |
| Scientific Title | The role of reactivation of human herpes virus in drug-induced hypersensitivity syndrome |
| Date of disclosure of the study information | 2013/01/07 |
| Last modified on | 2014/03/30 01:24:19 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The role of reactivation of human herpes virus in drug-induced hypersensitivity syndrome
Acronym
The role of reactivation of human herpes virus in drug-induced hypersensitivity syndrome
Scientific Title
The role of reactivation of human herpes virus in drug-induced hypersensitivity syndrome
Scientific Title:Acronym
The role of reactivation of human herpes virus in drug-induced hypersensitivity syndrome
Region
| Japan |
Condition
Condition
Drug-induced hypersensitivity syndrome
Classification by specialty
| Dermatology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To clarify the pathogenic mechanism of drug-induced hypersensitivity syndrome
Basic objectives2
Others
Basic objectives -Others
To clarify the pathogenic mechanism of drug-induced hypersensitivity syndrome
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Viral DNA amount and the concentration of cytokine/ chemokine in blood and saliva
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Maneuver |
Interventions/Control_1
Drug-induced hypersensitivity syndrome group
Interventions/Control_2
Healthy control group
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients with drug-induced hypersensitivity syndrome
Key exclusion criteria
Patients regarded as inadequate
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tomoya Watanabe |
Organization
Yokohama City University Graduate School of Medicine
Division name
Environmental Immuno-Dermatology
Zip code
Address
Fukuura 3-9, Kanazawa, Yokohama
TEL
045-787-2675
nabetomo0968@yahoo.co.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tomoya Watanabe |
Organization
Yokohama City University Graduate School of Medicine
Division name
Environmental Immuno-Dermatology
Zip code
Address
Fukuura 3-9, Kanazawa, Yokohama
TEL
045-787-2675
Homepage URL
nabetomo0968@yahoo.co.jp
Sponsor or person
Institute
Yokohama City University Graduate School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Yokohama City University Graduate School of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Nara Medical University
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 01 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2012 | Year | 11 | Month | 12 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 01 | Month | 07 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 01 | Month | 06 | Day |
Last modified on
| 2014 | Year | 03 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011382
